Search Results | New Search

City of Hope
Also Known As: COH
1500 E Duarte Rd Duarte, CA 91010

GENERAL INFORMATION

Who We Are

*Please note: City of Hope's national financials are listed under the Duarte, CA address. To visit these listings, click on the following: EIN #95-1683875 and EIN #95-3435919. The remainder of City of Hope's listings are from affiliate branches who file their 990's individually.

City of Hope, an innovative biomedical research, treatment and educational institution, is dedicated to the prevention and cure of cancer and other life-threatening diseases, guided by a compassionate patient-centered philosophy, and supported by a national foundation of humanitarian philanthropy.

• This organization is a 501(c)(3) Public Charity .
• This organization is required to file an IRS Form 990 or 990-EZ.
• Financial information in this report is derived from the organization's September 30, 2008 Form 990.
• Additional narrative information in this report was last supplied by the organization on February 26, 2009.
• It makes its audited financial statements available to the public upon request.
• Contributions are deductible, as provided by law.

How to Help

This organization is seeking funds from contributions and grants. These funds will be used for unrestricted operating expenses, special projects, building improvements and endowments.

Location(s) Served

• National

NTEE Code

• E24—Hospital (Specialty)
• H30—Cancer Research
• H99—Other Medical Research N.E.C.

Chief Executive

Dr. Michael A. Friedman, MD

Chief Executive Profile

Michael A. Friedman, M.D., has held executive positions in academia, government and private industry. He served as acting commissioner of the U.S. Food and Drug Administration, and associate director of the Cancer Therapy Evaluation Program within the Division of Cancer Treatment at the National Cancer Institute, National Institutes of Health. Prior to his current tenure as president and chief executive officer at City of Hope, he served as chief medical officer for biomedical preparedness at the Pharmaceutical Research and Manufacturers of America and senior vice president, Research & Development, Medical and Public Policy, for Pharmacia Corporation. An enthusiastic leader and educator, Dr. Friedman, was also an associate professor and director of the Clinical Research Program at the University of California at San Francisco. His scholarly activities include authorship of several book chapters and more than 150 scientific articles in prestigious journals.

BOARD OF DIRECTORS

MISSION AND PROGRAMS

Mission

City of Hope, an innovative biomedical research, treatment and educational institution, is dedicated to the prevention and cure of cancer and other life-threatening diseases, guided by a compassionate, patient-centered philosophy and supported by a national foundation of humanitarian philanthropy.

Programs

City of Hope is a world leader in bone marrow transplantation; leukemia; musculoskeletal, sarcoma and solid tumors; neurological tumors; new agents for pediatrics patients; and pain management.

Our renowned physicians have created treatment programs for cancer as well as diabetes and other life-threatening illnesses. At least $2.5 million is invested in research each week. The Beckman Research Institute is exploring how bone marrow transplantations (BMT) can be used to treat HIV/AIDS and autoimmune diseases such as multiple sclerosis and lupus. The link between the laboratory and the bedside means that patients receive lifesaving treatments without delay.

Additional Comments from the Organization

At any given time, City of Hope conducts more than 300 clinical studies, involving 25-35 percent of its eligible patients, nearly double the usual percentage at other cancer centers.

City of Hope consistently ranks among the top charities in the nation, with 85 cents out of every dollar spent going towards fighting cancer and other life-threatening illnesses. It was recently ranked as the fourth best health charity by Smart Money Magazine. In July 2002, U.S.News & World Report recognized City of Hope as one of America's best hospitals. The 2003 America's Best Hospitals rankings included City of Hope among the nation's top 50 medical centers for cancer treatment.

GOALS AND RESULTS

Accomplishments for Fiscal Year Ending December 31, 2006

1. City of Hope opened the Rita Cooper Finkel and J. William Finkel Women's Health Center, marking a significant step forward in the treatment and prevention of breast cancer and other medical issues affecting women.
2. Research throughout City of Hope is yielding exciting results using siRNA, or small interfering RNA. RNA is a chemical cousin of DNA, and siRNA can control how cells function - even turning off disease processes, including those of HIV/AIDS. Current work at City of Hope includes creating immune cells that produce siRNAs that cause genetic material in HIV to be diced into pieces, effectively stopping the virus. Another siRNA project offers even more hope. Researchers in Molecular Medicine and Pediatrics are designing siRNA molecules that can inhibit genes responsible for immune recognition. This would permit anyone to donate stem cells to a person needing a bone marrow transplant, eliminating the need for specific donor-recipient matches.
3. City of Hope is consistently recognized by the major regulating bodies as an outstanding organization. The triannual Combined Accreditation and Licensing Survey (CALS), including the Joint Commission on the Accreditation of Healthcare Organizations, the California Department of Health Services and the California Medical Association, ranked City of Hope in the top 1 percent of all U.S. hospitals surveyed in 2002 with City of Hope's highest score ever - 99 out of 100. In addition, patients recognize the superb care available at City of Hope. The 2003 Patients' Evaluation of Performance in California (PEP-C) project, the largest publicly reported and most comprehensive hospital patient survey of its kind in the nation awarded City of Hope 3 stars (the highest rating) in each of 7 survey categories.

Objectives for Fiscal Year Beginning January 1, 2007

1. Islet cell transplantation offers hope to sufferers of type 1 diabetes, who require a lifetime of daily injections. Islet cells can be transplanted into a recipient's liver to produce insulin naturally. In 2001, City of Hope was designated as one of 10 federally funded Islet Cell Resource (ICR) Centers responsible for processing and distributing islet cells to transplant programs across the nation. City of Hope recently received a $5 million grant enabling us to operate as the Administrative and Bioinformatics Coordinating Center for the nationwide ICR program. City of Hope will develop standard operating procedures, facilitate clinical trial operations, and correlate the resulting clinical data, as well as analyzing the success of transplant outcomes.
2. Cancer is caused when cells grow out of control. The disease has several causes, one of which is malfunction in a biochemical switch that shuts off the genes that control cell division, leading to uncontrolled cell growth. City of Hope is actively developing a promising anticancer agent known as FdCyd. FdCyd can affect genes so that these 'switches' turn back on and control cell growth. Side effects of the drug appear to be nearly nonexistent in testing, a great improvement over similar compounds.

FINANCIAL DATA

Revenues and Expenses: Fiscal Year Ending September 30, 2008

Balance Sheet: Fiscal Year Ending September 30, 2008

Note: The balance sheet gives a snapshot of the financial health of an organization at a particular point in time. An organization's total assets should generally exceed its total liabilities, or it cannot long survive, but the types of assets and liabilities also must be considered. For instance, an organization's current assets (cash, receivables, securities, etc.) should be sufficient to cover its current liabilities (payables, deferred revenue, current year loan and note payments). Otherwise, the organization may face solvency problems. On the other hand, an organization whose cash and equivalents greatly exceed its current liabilities might not be putting its money to best use.

Search Results | New Search

Copyright 2010, Philanthropic Research, Inc. All Rights Reserved. | Policies | Standards for Internet Philanthropy

GuideStar is the registered trademark and operating name of Philanthropic Research, Inc., a 501(c)(3) nonprofit organization.

Any other use, including resale of the information or use for commercial gain, is prohibited, except in accordance with a GuideStar licensing agreement.